Literature DB >> 18328949

Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.

Léon Mutesa1, Geneviève Pierquin, Nicolas Janin, Karin Segers, Caroline Thomée, Massimo Provenzi, Vincent Bours.   

Abstract

Noonan syndrome (NS) is an autosomal dominant disorder characterized by short stature, typical craniofacial dysmorphism, skeletal anomalies, congenital heart defects, and predisposition to malignant tumors. In approximately 50% of cases, the disease is caused by missense mutations in the PTPN11 gene. To date, solid tumors, and particularly brain tumors and rhabdomyosarcomas, have been documented in patients with NS; however, few cases of neuroblastoma associated with NS have been reported. Here we report an unusual case of neuroblastoma with mediastinal, retroperitoneal, and medullar locations associated in a NS patient carrying a PTPN11 germline missense mutation (p.G60A). This missense mutation occurs within the N-SH2 domain of the PTPN11 gene and has been reported to be associated with acute leukemia in NS patients. The association of this p.G60A PTPN11 mutation with neuroblastoma provides new evidence that gain of function PTPN11 mutations may play an important role in the pathogenesis of solid tumors associated with Noonan syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328949     DOI: 10.1016/j.cancergencyto.2007.12.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

Review 1.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

2.  Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.

Authors:  Ming-Liang He; Ying Chen; Quan Chen; Yaqing He; Jing Zhao; Jun Wang; Huanming Yang; Hsiang-Fu Kung
Journal:  Am J Cancer Res       Date:  2011-03-30       Impact factor: 6.166

Review 3.  Genetic susceptibility to neuroblastoma.

Authors:  Vanessa P Tolbert; Grace E Coggins; John M Maris
Journal:  Curr Opin Genet Dev       Date:  2017-04-28       Impact factor: 5.578

Review 4.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

Review 5.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Authors:  Kristopher R Bosse; John M Maris
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

6.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.

Authors:  Marjolijn C J Jongmans; Ineke van der Burgt; Peter M Hoogerbrugge; Kees Noordam; Helger G Yntema; Willy M Nillesen; Roland P Kuiper; Marjolijn J L Ligtenberg; Ad Geurts van Kessel; J Han J M van Krieken; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

7.  Noonan syndrome - a new survey.

Authors:  Alireza Tafazoli; Peyman Eshraghi; Zahra Kamel Koleti; Mohammadreza Abbaszadegan
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

Review 8.  Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.

Authors:  Stefano Stagi; Vittorio Ferrari; Marta Ferrari; Manuela Priolo; Marco Tartaglia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

9.  PTPN11 hypomethylation is associated with gastric cancer progression.

Authors:  Lele Xu; Cong Zhou; Ranran Pan; Junjian Tang; Jinzhi Wang; Bin Li; Tianyi Huang; Shiwei Duan; Chunfang Xu
Journal:  Oncol Lett       Date:  2020-01-07       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.